Company Hansa Biopharma AB Mexican S.E.
Equities
HNSA N
SE0002148817
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
160.8 MXN | -.--% | -.--% | -.--% |
May. 31 | Hansa Biopharma Finalizes Patient Randomization for Use of Imlifidase inKidney Transplantation Trial | MT |
May. 31 | Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial | CI |
Business Summary
Number of employees: 166
Sales per Business
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Antibody-cleaving Enzyme Technology Platform
100.0
%
| 155 | 100.0 % | 134 | 100.0 % | -13.22% |
Sales per region
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Europe (excluding Sweden)
79.6
%
| 86 | 55.4 % | 107 | 79.6 % | +24.66% |
North America
20.4
%
| 64 | 41.6 % | 27 | 20.4 % | -57.34% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 18-03-19 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | Nov. 30 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 20-05-28 |
- | - | ||
Klaus Sindahl
IRC | Investor Relations Contact | - | 19-04-28 |
Matthew Shaulis
PRN | Corporate Officer/Principal | - | 23-03-15 |
Max Sakajja
PRN | Corporate Officer/Principal | 43 | 16-12-31 |
Anne Lanner
HRO | Human Resources Officer | 55 | 19-01-17 |
Vincenza Nigro
PRN | Corporate Officer/Principal | - | 18-09-16 |
Magnus Korsgren
PRN | Corporate Officer/Principal | 55 | 21-03-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 73 | 18-05-28 | |
Peter Nicklin
CHM | Chairman | 61 | 22-06-29 |
Mats Blom
BRD | Director/Board Member | 59 | 19-05-21 |
Eva Nilsagård
BRD | Director/Board Member | 60 | 19-05-21 |
Hilary Malone
BRD | Director/Board Member | 59 | 21-05-11 |
Andreas Eggert
BRD | Director/Board Member | 56 | 18-05-28 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 2,362,445 | 0 | 2,362,445 ( 100.00 %) | 88.64 % |
Stock B | 1 | 52,443,962 | 48,580,000 ( 92.63 %) | 0 |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
HANSA BIOPHARMA AB 90.93% | 2,362,445 | 90.93% | 6,229,035 $ |
Company contact information
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- HNSA Stock
- HNSA N Stock
- Company Hansa Biopharma AB